跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
DUPIXENT - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
DUPIXENT
Authorized
STANDARD
DUPIXENT
sanofi-aventis canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
0d55411cbf066622
Company
sanofi-aventis canada inc
Type
Standard
Approval Details
Approval Id
0d55411cbf066622
Drug Approval Canada Name
DUPIXENT
Product Name
DUPIXENT
Status
Marketed
Status Date
2021-05-27
Original Market Date
2021-05-27
Din
02510049
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Schedule D , Prescription
Ahfs
84:06.28
Atc Original
D11AH05 DUPILUMAB
Atc Name
d 11 ah 05
Aig Number
0159790001
Company Name
sanofi-aventis canada inc
Company Address
1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4
Active Ingredients
DUPILUMAB
300 MG / 2 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
0d55411cbf066622
Type
Standard
Back to Health Canada Approvals